Hemosol B0

Hemosol B0 is an intravenous solution that contains calcium, magnesium, sodium, chloride, hydrogen carbonate and lactic acid. It is supplied as a sterile liquid for use in haemodialysis and other intravenous applications. The product is marketed in the European Union and is available only by prescription. It is designed to help maintain electrolyte balance and acid‑base status during renal replacement therapy.

Hemosol B0 is used in clinical settings where precise control of electrolytes and acid‑base balance is required, especially during renal replacement procedures. It may be employed for the following purposes:

- Replacement of calcium, magnesium and sodium losses during haemodialysis. - Correction of metabolic acidosis in patients receiving dialysis. - Maintenance of plasma volume and osmotic balance in critically ill patients. - Support of cardiac and neuromuscular function when electrolyte disturbances are present. - Adjunct therapy for patients with chronic kidney disease undergoing intermittent dialysis.

Side effects of Hemosol B0 are generally related to its electrolyte composition and the rate of infusion. They are reported in clinical practice and may vary in frequency and severity.

Common: - Mild nausea or vomiting. - Transient hypotension or dizziness during rapid infusion. - Mild headache. - Local irritation at the infusion site. - Temporary changes in serum calcium or magnesium levels.

Serious: - Hypercalcemia leading to cardiac arrhythmias. - Severe metabolic alkalosis. - Pulmonary edema from excessive volume load. - Acute coronary syndrome in patients with underlying heart disease. - Severe electrolyte imbalance requiring urgent medical intervention.

When prescribing or administering Hemosol B0, clinicians should observe several safety considerations to minimize risk.

- Monitor serum calcium, magnesium, sodium and bicarbonate levels before, during, and after infusion. - Avoid use in patients with known hypercalcemia or severe metabolic alkalosis. - Adjust infusion rate in patients with compromised cardiac function or fluid overload risk. - Use caution in individuals receiving other electrolyte-containing solutions to prevent cumulative excess. - Ensure compatibility with other intravenous medications; incompatibility may cause precipitation. - Store the solution according to manufacturer guidelines to maintain sterility and potency.

Hemosol B0 may interact with other medications or solutions administered intravenously. Awareness of potential interactions helps maintain patient safety.

Avoid: - Simultaneous infusion of calcium‑containing solutions with phosphate binders, which can precipitate calcium phosphate. - Co‑administration with high‑dose potassium supplements, as electrolyte shifts may become unpredictable.

Use with caution: - Loop diuretics, which can amplify calcium and magnesium losses. - ACE inhibitors or ARBs, which may affect renal handling of electrolytes. - Beta‑blockers, especially in patients prone to bradycardia when calcium levels rise. - Anticoagulants used during dialysis, as electrolyte shifts can influence coagulation parameters.